Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Ambroxol in Newly Diagnosed GBA1 Parkinson Disease
NCT06193421Phase 2Recruiting
- Sponsor
- Agyany Pharma
- Start
- Oct 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ambroxol hydrochloride oral solution in Parkinson's disease (PD), sponsored by Agyany Pharma. Primary endpoints: Treatment-Emergent Adverse Events at 12 months, Potentially Clinically Significant Laboratory Abnormalities at 12 months and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
Ambroxol hydrochloride oral solution
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06193421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193421.